Forbes Real Time
EndoChoice -- Guts, Glory & A $100M IPO
There was a time when going public was all the rage. It still is for serial entrepreneurs who expect to hit major scale and want a lower cost of capital to continue feeding that scale. For some people an IPO isn’t in the cards but for Atlanta-based EndoChoice, a GI medical technology company, it was in the plan before they did their first seed round. Here’s a look at the major milestones they passed from seed to IPO and the logic behind their ascent from a napkin in 2008 to $61Million in revenue in 2015 with ready capital to keep going.
No comments:
Post a Comment